Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €61.11 EUR
Change Today -1.45 / -2.31%
Volume 71.0
8AK On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:05 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

alkermes plc (8AK) Snapshot

Open
€61.23
Previous Close
€62.56
Day High
€62.31
Day Low
€60.96
52 Week High
03/5/15 - €67.90
52 Week Low
10/13/14 - €30.36
Market Cap
9.1B
Average Volume 10 Days
68.0
EPS TTM
€-0.64
Shares Outstanding
148.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALKERMES PLC (8AK)

alkermes plc (8AK) Related Businessweek News

View More BusinessWeek News

alkermes plc (8AK) Details

Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. The company offers RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia schizoaffective disorder; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; and VIVITROL for alcohol and opioid dependence. It is also developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a Phase II study medicine to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is under Phase I study to treat multiple sclerosis; ALKS 7106, a drug candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary investigational biologic cancer immunotherapy product that is under pre-clinical stage. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. Alkermes Public Limited Company was founded in 1987 and is headquartered in Dublin, Ireland.

1,300 Employees
Last Reported Date: 02/24/15
Founded in 1987

alkermes plc (8AK) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $854.7K
President
Total Annual Compensation: $630.6K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $468.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $468.1K
Chief Compliance Officer, Chief Legal Officer...
Total Annual Compensation: $459.4K
Compensation as of Fiscal Year 2014.

alkermes plc (8AK) Key Developments

Alkermes Not To Be Sold

Alkermes plc (NasdaqGS:ALKS) Chief Executive Officer said he is not interested in selling company. He thinks the company's research pipeline is attractive to potential buyers, but said "this is not the time when we're interested in being a seller."

Alkermes plc - Special Call

To discuss the six-month data of ALKS 3831 for the treatment of schizophrenia

Alkermes plc Announces Data from Studies of its Pipeline of Central Nervous System Drug Candidates

Alkermes plc announced that data from studies of the company’s pipeline of central nervous system (CNS) drug candidates in schizophrenia and depression, including ALKS 3831, aripiprazole lauroxil and ALKS 5461, will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Fla., June 22-25, 2015. Alkermes data presentations at ASCP include: ALKS 3831: Oral presentation, “ALKS 3831: A Novel Drug Candidate for the Treatment of Schizophrenia,” will be presented during the Pharmaceutical Pipeline symposium on June 22, 2015, 2:00 p.m. – 4:00 p.m. EDT. Poster #T6, “ALKS 3831: A Novel Drug Candidate for the Treatment of Schizophrenia,” will be available during Poster Session I, June 23, 2015, 11:15 a.m. – 1:00 p.m. EDT. Oral presentation, “A Phase 2, Randomized, Olanzapine-Controlled Study of the Safety, Tolerability and Efficacy of ALKS 3831 in Adults with Schizophrenia,” will be presented on June 23, 2015, 3:30 p.m. – 4:30 p.m. EDT. Aripiprazole Lauroxil: Poster #T88, “Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles, and Related Safety Considerations in Acute Schizophrenia,” will be available during Poster Session I, June 23, 2015, 11:15 a.m. – 1:00 p.m. EDT. Oral presentation, “Efficacy and Safety of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia: Results from a Double-Blind Placebo-Controlled Study,” will be presented on June 23, 2015, 3:30 p.m. – 4:30 p.m. EDT. Poster #W88, “Effect of Aripiprazole Lauroxil on Personal and Social Functioning and Health-Related Quality of Life Among Patients with Schizophrenia,” will be available during Poster Session II, June 24, 2015, 12:00 p.m. – 2:00 p.m. EDT. ALKS 5461: Oral presentation “ALKS 5461 as Adjunctive Treatment of Major Depressive Disorder: Phase 3, Randomized, Double-Blind Study (FORWARD-1) Evaluating Two Titration Schedules,” will be presented on June 23, 2015, 3:30 p.m. – 4:30 p.m. EDT. Poster #W36, “Combinations of Buprenorphine and Samidorphan Modulate Glutamate and GABA Transmission in the Medial Prefrontal Cortex and Ventral Hippocampus of Male Wistar Rats,” will be available during Poster Session II, June 24, 2015, 12:00 p.m. – 2:00 p.m. EDT.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8AK:GR €61.11 EUR -1.45

8AK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $31.87 USD -1.02
Emergent BioSolutions Inc $32.40 USD -1.20
Incyte Corp $103.74 USD -1.75
Jazz Pharmaceuticals PLC $190.68 USD -2.34
Lupin Ltd 1,640 INR +30.75
View Industry Companies
 

Industry Analysis

8AK

Industry Average

Valuation 8AK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.8x
Price/Book 7.3x
Price/Cash Flow 422.1x
TEV/Sales 14.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit www.alkermes.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.